Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) presents as an unmet clinical challenge for drug delivery due to its unique hypoxic biology. Vinblastine-N-Oxide (CPD100) is a hypoxia-activated prodrug (HAP) that selectively converts to its parent compound, vinblastine, a potent cytotoxic agent, under oxygen...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Vidhi M. Shah, Craig Dorrell, Adel Al-Fatease, Brittany L. Allen-Petersen, Yeonhee Woo, Yuliya Bortnyak, Rohi Gheewala, Brett C. Sheppard, Rosalie C. Sears, Adam WG. Alani
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2022-03-01
Edice:	Pharmaceutics
Témata:	hypoxia-activated prodrug liposome drug delivery organoids pancreatic cancer
On-line přístup:	https://www.mdpi.com/1999-4923/14/4/713
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!